Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Inclusion Criteria:

• Ability to understand and sign a written informed consent form

• Plasma HIV-1 RNA levels ≥ 2,500 copies/mL at screening

• No prior use of any approved or experimental anti-HIV drug for any length of time

• Screening genotype report showing sensitivity to EFV, FTC, TDF, and lack of the RPVmutations K101E/P, E138A/G/K/Q/R, Y181C/I/V, and H221Y

• Normal ECG

• Hepatic transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) ≤ 5 x the upper limit of the normal range (ULN)

• Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin

• Adequate hematologic function

• Serum amylase ≤ 5 x ULN (participants with serum amylase > 5 x ULN remained eligibleif serum lipase was ≤ 5 x ULN)

• Adequate renal function

• Males and Females of childbearing potential must have agreed to utilize highlyeffective contraception methods (two separate forms of contraception, one of whichmust be an effective barrier method, or be non-heterosexually active, practice sexualabstinence or have a vasectomized partner) from screening throughout the duration ofstudy period and for 12 weeks following the last dose of study drug.

• Adult (≥ 18 years) males or non-pregnant females

Exclusion Criteria:

• A new AIDS-defining condition diagnosed within the 30 days prior to screening

• Females who were breastfeeding

• Positive serum pregnancy test (female of childbearing potential)

• Proven or suspected acute hepatitis in the 30 days prior to study entry

• Subjects receiving drug treatment for hepatitis C, or subjects who were anticipated toreceive treatment for hepatitis C during the course of the study

• Subjects experiencing decompensated cirrhosis

• Had an implanted defibrillator or pacemaker

• Current alcohol or substance abuse

• A history of malignancy within the past 5 years or ongoing malignancy other thancutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneoussquamous carcinoma

• Active, serious infections requiring parenteral antibiotic or antifungal therapywithin 30 days prior to baseline

• Receiving ongoing therapy or anticipated to need to initiate drugs or herbal/naturalsupplements during the study that are contraindicated or not recommended for use,including drugs not to be used with FTC, EFV, RPV, or TDF; or subjects with knownallergies to the excipients of the FTC/RPV/TDF or EFV/FTC/TDF single-tablet regimens

• Participation in any other clinical trial without prior approval from the sponsor wasprohibited while participating in this trial.

• Had been treated with immunosuppressant therapies or chemotherapeutic agents within 3months of study screening, or expected to receive these agents or systemic steroidsfor immunosuppression during the study (eg, corticosteroids, immunoglobulins, andother immune-based or cytokine-based therapies)

• Had any other clinical condition or prior therapy that, in the opinion of theInvestigator, would have made the participant unsuitable for the study or unable tocomply with the dosing requirements